Patent classifications
A61K36/884
Oral compositions for bladder regulation and uses thereof
Oral compositions for supporting bladder function, reduce frequency of urination, and/or improve or maintain bladder control, suitable for oral administration, are described. Methods of use and uses are described, which include the step of administering an effective amount of the oral compositions to supporting bladder function, reduce frequency of urination, and/or improve or maintain bladder control.
Oral compositions for bladder regulation and uses thereof
Oral compositions for supporting bladder function, reduce frequency of urination, and/or improve or maintain bladder control, suitable for oral administration, are described. Methods of use and uses are described, which include the step of administering an effective amount of the oral compositions to supporting bladder function, reduce frequency of urination, and/or improve or maintain bladder control.
Oral compositions for bladder regulation and uses thereof
Oral compositions for supporting bladder function, reduce frequency of urination, and/or improve or maintain bladder control, suitable for oral administration, are described. Methods of use and uses are described, which include the step of administering an effective amount of the oral compositions to supporting bladder function, reduce frequency of urination, and/or improve or maintain bladder control.
Antiviral pharmaceutical compositions and method of manufacturing
The present disclosure provides compositions comprising combinations of one or more lectins, sulfated polysaccharides from marine algae, and cannabinoids and a pharmaceutically acceptable excipient or mixtures of excipients and methods of preparing such compositions.
Antiviral pharmaceutical compositions and method of manufacturing
The present disclosure provides compositions comprising combinations of one or more lectins, sulfated polysaccharides from marine algae, and cannabinoids and a pharmaceutically acceptable excipient or mixtures of excipients and methods of preparing such compositions.
Method for treating psoriasis
The present invention relates to a method for treating psoriasis including: administering a Chinese medicine composition to a subject in need thereof; wherein the Chinese medicine composition is an extract of a first mixture including Pimenta officinalis, Paeonia veitchii, Anastatica hierochuntica, Zingiber officinale, Scutellaria baicalensis, and Ziziphus jujube.
Method for treating psoriasis
The present invention relates to a method for treating psoriasis including: administering a Chinese medicine composition to a subject in need thereof; wherein the Chinese medicine composition is an extract of a first mixture including Pimenta officinalis, Paeonia veitchii, Anastatica hierochuntica, Zingiber officinale, Scutellaria baicalensis, and Ziziphus jujube.
Method of treating meningioma
The present invention relates to a method of treating meningioma including administering a Chinese medicine composition to a subject in need thereof; wherein the Chinese medicine composition is an extract of a first mixture comprising Coptis chinensis, Phellodendron amurense, Glycyrrhiza uralensis, Atractylodes lancea, Artemisia carvifolia, Anemarrhena asphodeloides, and Cortex Lycii.
Method of treating meningioma
The present invention relates to a method of treating meningioma including administering a Chinese medicine composition to a subject in need thereof; wherein the Chinese medicine composition is an extract of a first mixture comprising Coptis chinensis, Phellodendron amurense, Glycyrrhiza uralensis, Atractylodes lancea, Artemisia carvifolia, Anemarrhena asphodeloides, and Cortex Lycii.
Manufacturing method of an herbal medicinal tablet formulation for treating obesity which can be prescribed based on sasang constitutional medicine
An embodiment of the present invention provides a manufacturing method of an herbal medicinal tablet formulation for treating obesity which is prescribed based on Sasang constitutional medicine, comprises manufacturing a concentrated ephedra powder agent so that an ephedrine content is 3.0-4.0%; determining a weight of the concentrated ephedra powder agent according to each constitution of Sasang constitutional medicine, and manufacturing a side effect-preventing powder agent for each constitution to prevent and suppress side effects according to constitution of Sasang constitutional medicine with respect to the weight of the concentrated ephedra powder agent; mixing the concentrated ephedra powder agent and the side effect-preventing powder agent with a variance of a weight ratio therebetween in consideration of weight, obesity, constitution of Sasang constitutional medicine, and side effects; and tableting the mixture of the prepared ephedra powder agent and side effect-preventing powder agent.